Select your country

13.11.2018
STADA’s €300,000,000 1.75% Senior Notes due 2022: announcement of an instruction to grant in rem securities

STADA’s €300,000,000 1.75% Senior Notes due 2022: announcement of an instruction to grant in rem securities

Read more

18.09.2018
Voting results of the bondholders’ meeting concerning the STADA-Bond 2015/2022

Voting results of the bondholders’ meeting concerning the STADA-Bond 2015/2022

Read more

12.09.2018
STADA invites the holders of the STADA Bond to participate in the bondholders‘ meeting

STADA invites the holders of the STADA Bond to participate in the bondholders‘ meeting

Read more

09.08.2018
STADA’s business development in the first six months of 2018 as expected

STADA’s business development in the first six months of 2018 as expected

Read more

06.08.2018
Strategic portfolio expansion

Strategic portfolio expansion

STADA becomes Majority Shareholder of BIOCEUTICALS Arzneimittel AG

Read more

20.07.2018
STADA Launches Anti-Cancer Drug Pemetrexed

STADA Launches Anti-Cancer Drug Pemetrexed

STADAPHARM GmbH will from now on distribute cytostatic drug Pemetrexed STADA®.

Read more

18.07.2018
STADA Repurchases Rights for Ladival

STADA Repurchases Rights for Ladival

STADA Arzneimittel AG and Ladival GmbH & Co KG have agreed to transfer the rights for the sunscreen Ladival back to the German pharmaceu…

Read more

17.07.2018
STADA: Voting results of the bondholders’ meeting on July 17, 2018 concerning the STADA-Bond 2015/2022: Appointment of One Square Advisory Services GmbH as joint representative and adjournment of the further agenda items

STADA: Voting results of the bondholders’ meeting on July 17, 2018 concerning the STADA-Bond 2015/2022: Appointment of One Square Advisory Services GmbH as joint representative and adjournment of the further agenda items

Read more

12.07.2018
Xbrane and STADA enter into a co-development agreement for Xlucane

Xbrane and STADA enter into a co-development agreement for Xlucane

Xbrane Biopharma AB (“Xbrane”) and STADA Arzneimittel AG (“STADA”) have entered into a co-development agreement for Xlucane, a Lucentis® (ra…

Read more

11.07.2018
STADA Arzneimittel AG: Announcement of the results of the Tender Offer regarding the STADA-Bond 2015/2022

STADA Arzneimittel AG: Announcement of the results of the Tender Offer regarding the STADA-Bond 2015/2022

Read more

29.06.2018
NOT FOR DISTRIBUTION TO ANY U.S. PERSON OR IN OR INTO OR TO ANY PERSON LOCATED IN THE UNITED STATES.

NOT FOR DISTRIBUTION TO ANY U.S. PERSON OR IN OR INTO OR TO ANY PERSON LOCATED IN THE UNITED STATES.

Read more

15.06.2018
STADA recovers top-selling product and will distribute the Parkinson's medication in Germany and Scandinavia in the future

STADA recovers top-selling product and will distribute the Parkinson's medication in Germany and Scandinavia in the future

STADA continues to advance its strategic reorientation.

Read more

08.06.2018
STADA Arzneimittel AG: Consent Solicitation for STADA Euro bond 2015/2022

STADA Arzneimittel AG: Consent Solicitation for STADA Euro bond 2015/2022

STADA has today published the solicitation to the noteholders of the STADA Euro bond 2015/2022.

Read more

06.06.2018
STADA: Annual General Meeting approves agenda items with a large majority

STADA: Annual General Meeting approves agenda items with a large majority

STADA Arzneimittel AG announced today that the Company’s shareholders approved all agenda items with a large majority that were put to a vot…

Read more

03.05.2018
STADA with solid business development in the first quarter of 2018

STADA with solid business development in the first quarter of 2018

Read more

16.04.2018
Changes in the management team of STADA

Changes in the management team of STADA

STADA is systematically pushing ahead with the new strategy announced in March.

Read more

23.03.2018
STADA: Executive Board of STADA Arzneimittel AG decides to file application related to change of sub-segment of the stock exchange

STADA: Executive Board of STADA Arzneimittel AG decides to file application related to change of sub-segment of the stock exchange

STADA: Executive Board of STADA Arzneimittel AG decides to file application related to change of sub-segment of the stock exchange

Read more

20.03.2018
STADA: Domination and profit and loss transfer agreement between STADA Arzneimittel AG and Nidda Healthcare GmbH takes effect / beginning of acceptance period for severance offer

STADA: Domination and profit and loss transfer agreement between STADA Arzneimittel AG and Nidda Healthcare GmbH takes effect / beginning of acceptance period for severance offer

STADA: Domination and profit and loss transfer agreement between STADA Arzneimittel AG and Nidda Healthcare GmbH takes effect / beginning of…

Read more

08.03.2018
CEO Albrecht to modernize STADA – Biosimilars to focus on oncology, CNS, diabetes and ophthalmology

CEO Albrecht to modernize STADA – Biosimilars to focus on oncology, CNS, diabetes and ophthalmology

CEO Albrecht to modernize STADA – Biosimilars to focus on oncology, CNS, diabetes and ophthalmology

Read more

08.03.2018
More focused and aggressive

More focused and aggressive

At the press conference on March 8, 2018 STADA CEO Dr. Claudio Albrecht presented his vision for STADA and the company’s new strategy. In th…

Read more

08.03.2018
STADA: Executive Board and Supervisory Board of STADA Arzneimittel AG resolve on a proposal for the appropriation of profits and propose a dividend in the amount of €0.11 per share

STADA: Executive Board and Supervisory Board of STADA Arzneimittel AG resolve on a proposal for the appropriation of profits and propose a dividend in the amount of €0.11 per share

STADA: Executive Board and Supervisory Board of STADA Arzneimittel AG resolve on a proposal for the appropriation of profits and propose a d…

Read more

02.02.2018
STADA: General Meeting approves domination and profit and loss transfer agreement with Nidda Healthcare GmbH

STADA: General Meeting approves domination and profit and loss transfer agreement with Nidda Healthcare GmbH

The Extraordinary General Meeting of STADA Arzneimittel AG (STADA) on February 2, 2018 with a majority of 99 percent approved the conclusion…

Read more

02.02.2018
STADA: General Meeting approves domination and profit and loss transfer agreement with Nidda Healthcare GmbH

STADA: General Meeting approves domination and profit and loss transfer agreement with Nidda Healthcare GmbH

Read more

01.02.2018
STADA set for continuity: Peter Goldschmidt to succeed Claudio Albrecht as CEO on 1 September 2018

STADA set for continuity: Peter Goldschmidt to succeed Claudio Albrecht as CEO on 1 September 2018

Read more

01.02.2018
STADA Arzneimittel AG: Supervisory Board of STADA Arzneimittel AG appoints Peter Goldschmidt as new Chairman of the Executive Board as of September 1, 2018

STADA Arzneimittel AG: Supervisory Board of STADA Arzneimittel AG appoints Peter Goldschmidt as new Chairman of the Executive Board as of September 1, 2018

The Supervisory Board of STADA Arzneimittel AG appointed Peter Goldschmidt today as new Chairman of the Executive Board as of September 1, 2…

Read more

18.01.2018
Internationalization of OTC brands: STADA agrees to early termination of license agreement with Sanofi for head lice lotion Hedrin

Internationalization of OTC brands: STADA agrees to early termination of license agreement with Sanofi for head lice lotion Hedrin

STADA is advancing the internationalization of its OTC brand business.

Read more